Skip to main content
. 2014 Feb 5;9(2):e88176. doi: 10.1371/journal.pone.0088176

Figure 4. TMP affects whole-blood flow.

Figure 4

Adult SD rats were randomized to treatment groups, which received daily i.p. injections of TMP or the control vehicle (normal saline) at a dose of 100 mg/kg in 500 µL for 3 days. (A) TMP decreases the whole-blood viscosity at shear rates of 150, 300, and 1000 sec-1 (14.50±2.49 vs. 8.54±1.15, 6.17±0.88 vs. 5.09±0.58, 4.96±0.64 vs. 4.15±0.26, respectively; *P<0.001; n = 6 rats/group). (B) TMP decreases ADP-induced platelet aggregation rate, the maximum platelet aggregation rate of (18.70±1.75 vs. 15.70±0.82), and the slope (24.70±2.42 vs. 20.50±1.87) (P<0.001; n = 6 rats/group). Platelets, lymphocytes and red blood cells were stained with anti-CXCR4 (red) primary antibodies, as described in Materials and Methods. The immunohistofluorescence analysis shows that CXCR4 expression of platelets (C), lymphocytes (D) and red blood cells (E) is significantly reduced after treatment with TMP.